NASDAQ:KURA Kura Oncology (KURA) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free KURA Stock Alerts $20.63 +0.04 (+0.19%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$20.26▼$21.2550-Day Range$17.53▼$23.5352-Week Range$7.41▼$24.17Volume605,625 shsAverage Volume1.29 million shsMarket Capitalization$1.57 billionP/E RatioN/ADividend YieldN/APrice Target$28.28 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Kura Oncology alerts: Email Address Kura Oncology MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside37.1% Upside$28.28 Price TargetShort InterestBearish15.93% of Float Sold ShortDividend StrengthN/ASustainability-0.76Upright™ Environmental ScoreNews Sentiment-0.50Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.35) to ($2.47) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.01 out of 5 starsMedical Sector2197th out of 5,430 stocksPharmaceutical Preparations Industry973rd out of 2,526 stocks 3.4 Analyst's Opinion Consensus RatingKura Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageKura Oncology has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted15.93% of the float of Kura Oncology has been sold short.Short Interest Ratio / Days to CoverKura Oncology has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in Kura Oncology has recently decreased by 2.79%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldKura Oncology does not currently pay a dividend.Dividend GrowthKura Oncology does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreKura Oncology has received a 73.98% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Kura Oncology is -0.76. Previous Next 0.8 News and Social Media Coverage News SentimentKura Oncology has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Kura Oncology this week, compared to 4 articles on an average week.Search InterestOnly 2 people have searched for KURA on MarketBeat in the last 30 days. This is a decrease of -88% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Kura Oncology to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kura Oncology insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.50% of the stock of Kura Oncology is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Kura Oncology are expected to decrease in the coming year, from ($2.35) to ($2.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kura Oncology is -9.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kura Oncology is -9.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKura Oncology has a P/B Ratio of 3.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsFW: 234x GainThis coin is an essential building block for an ongoing financial revolution of massive dimensions. As a big part of this revolution, the big banks of the world must connect to the blockchain.Click here. About Kura Oncology Stock (NASDAQ:KURA)Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.Read More KURA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KURA Stock News HeadlinesMay 3, 2024 | globenewswire.comKura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 2, 2024 | investorplace.comKURA Stock Earnings: Kura Oncology Misses EPS for Q1 2024May 3, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. May 2, 2024 | msn.comKura Oncology Q1 2024 Earnings PreviewMay 2, 2024 | finance.yahoo.comKura Oncology Reports First Quarter 2024 Financial ResultsMay 2, 2024 | globenewswire.comKura Oncology Reports First Quarter 2024 Financial ResultsApril 25, 2024 | globenewswire.comKura Oncology to Report First Quarter 2024 Financial ResultsApril 24, 2024 | uk.investing.comFDA grants breakthrough status for Kura Oncology's AML drug candicateMay 3, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. April 24, 2024 | americanbankingnews.comKura Oncology, Inc. (NASDAQ:KURA) Given Consensus Recommendation of "Moderate Buy" by BrokeragesApril 23, 2024 | americanbankingnews.comKura Oncology (NASDAQ:KURA) Given "Buy" Rating at HC WainwrightApril 23, 2024 | finanznachrichten.deKura Oncology, Inc.: Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AMLApril 22, 2024 | markets.businessinsider.comKura Oncology’s Buy Rating Affirmed by Analyst Joseph Pantginis Amid Breakthrough Therapy Designation and Promising Preclinical DataApril 22, 2024 | markets.businessinsider.comKura Oncology Gets FDA Breakthrough Therapy Designation For Ziftomenib In R/R NPM1-Mutant AMLApril 22, 2024 | marketwatch.comKura Oncology Gets Breakthrough Designation For Leukemia TherapyApril 22, 2024 | finance.yahoo.comKura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AMLApril 10, 2024 | msn.comImmunotherapy After Definitive Therapy Flops in Head and Neck CancerApril 10, 2024 | nasdaq.comValidea Detailed Fundamental Analysis - KURAApril 10, 2024 | globenewswire.comKura Oncology to Participate in Stifel Targeted Oncology ForumApril 10, 2024 | globenewswire.comKura Oncology to Participate in Stifel Targeted Oncology ForumApril 5, 2024 | globenewswire.comKura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 28, 2024 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on Celcuity (CELC)March 7, 2024 | markets.businessinsider.comBuy Rating Affirmed: Kura Oncology’s KO-2806 Shows Promising Clinical and Market PotentialMarch 6, 2024 | finanznachrichten.deKura Oncology, Inc.: Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell CarcinomaMarch 6, 2024 | globenewswire.comKura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell CarcinomaMarch 1, 2024 | globenewswire.comKura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 1, 2024 | markets.businessinsider.comBuy Rating for Kura Oncology Amid Strong Q4 Results and Promising Ziftomenib TrialsSee More Headlines Receive KURA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kura Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today5/03/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:KURA CUSIPN/A CIK1422143 Webwww.kuraoncology.com Phone(858) 500-8800FaxN/AEmployees142Year FoundedN/APrice Target and Rating Average Stock Price Target$28.28 High Stock Price Target$37.00 Low Stock Price Target$10.50 Potential Upside/Downside+37.9%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-152,630,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-36.30% Return on Assets-33.12% Debt Debt-to-Equity Ratio0.02 Current Ratio12.26 Quick Ratio12.26 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.35 per share Price / Book3.83Miscellaneous Outstanding Shares76,180,000Free Float71,991,000Market Cap$1.56 billion OptionableOptionable Beta0.89 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Troy Edward Wilson J.D. (Age 55)Ph.D., Chairman, CEO & President Comp: $1.22MMs. Kathleen Ford (Age 77)Chief Operating Officer Comp: $824.95kMs. Teresa Brophy Bair Esq. (Age 53)J.D., Chief Legal Officer & Corporate Secretary Comp: $705.38kDr. Stephen Dale M.D. (Age 52)Chief Medical Officer Comp: $855.3kMr. Thomas Doyle (Age 53)Senior Vice President of Finance & Accounting Mr. Pete De SpainExecutive Vice President of Investor Relations & Corporate CommunicationsDr. Roger Bakale Ph.D.Senior Vice President of Manufacturing & Supply ChainMs. Maureen Clancy M.B.A.VP and Global Head of Program Leadership & Project ManagementDr. Mollie Leoni M.D.Executive Vice President of Clinical DevelopmentMr. Brian T. Powl M.B.A. (Age 50)M.S., Chief Commercial Officer More ExecutivesKey CompetitorsDay One BiopharmaceuticalsNASDAQ:DAWNArdelyxNASDAQ:ARDXDynavax TechnologiesNASDAQ:DVAXProtagonist TherapeuticsNASDAQ:PTGXZai LabNASDAQ:ZLABView All CompetitorsInsiders & InstitutionsBNP Paribas Financial MarketsSold 42,305 shares on 5/1/2024Ownership: 0.065%Mirae Asset Global Investments Co. Ltd.Bought 4,659 shares on 5/1/2024Ownership: 0.054%Principal Financial Group Inc.Sold 1,578 shares on 4/29/2024Ownership: 0.023%China Universal Asset Management Co. Ltd.Bought 7,027 shares on 4/29/2024Ownership: 0.020%Simplex Trading LLCBought 9,900 shares on 4/25/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions KURA Stock Analysis - Frequently Asked Questions Should I buy or sell Kura Oncology stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" KURA shares. View KURA analyst ratings or view top-rated stocks. What is Kura Oncology's stock price target for 2024? 8 brokerages have issued 1 year price objectives for Kura Oncology's shares. Their KURA share price targets range from $10.50 to $37.00. On average, they predict the company's share price to reach $28.28 in the next twelve months. This suggests a possible upside of 37.1% from the stock's current price. View analysts price targets for KURA or view top-rated stocks among Wall Street analysts. How have KURA shares performed in 2024? Kura Oncology's stock was trading at $14.38 at the beginning of 2024. Since then, KURA stock has increased by 43.5% and is now trading at $20.63. View the best growth stocks for 2024 here. When is Kura Oncology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our KURA earnings forecast. How were Kura Oncology's earnings last quarter? Kura Oncology, Inc. (NASDAQ:KURA) announced its earnings results on Thursday, May, 2nd. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.56) by $0.03. Kura Oncology's revenue for the quarter was up .0% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.50) EPS. What ETFs hold Kura Oncology's stock? ETFs with the largest weight of Kura Oncology (NASDAQ:KURA) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Invesco Dorsey Wright Healthcare Momentum ETF (PTH).ALPS Medical Breakthroughs ETF (SBIO). What other stocks do shareholders of Kura Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kura Oncology investors own include Exelixis (EXEL), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Amarin (AMRN), Gilead Sciences (GILD), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP) and Advanced Micro Devices (AMD). Who are Kura Oncology's major shareholders? Kura Oncology's stock is owned by a variety of institutional and retail investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.24%), Aaron Wealth Advisors LLC (0.09%), BNP Paribas Financial Markets (0.06%), Mirae Asset Global Investments Co. Ltd. (0.05%), Principal Financial Group Inc. (0.02%) and China Universal Asset Management Co. Ltd. (0.02%). Insiders that own company stock include Kathleen Ford, Kirsten Flowers, Teresa Brophy Bair, Thomas James Doyle, Thomas Malley and Troy Edward Wilson. View institutional ownership trends. How do I buy shares of Kura Oncology? Shares of KURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KURA) was last updated on 5/3/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyUrgent Nvidia WarningAltimetryAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldThe Gold Grab of the CenturyColonial MetalsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithREAD THIS – If You Missed Out On The AI BoomBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kura Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
